The U.S. Senate passed a revised Biosecure Act as an amendment to the National Defense Authorization Act, authorizing restrictions on federal funding or contracting with designated 'biotechnology companies of concern.' The amendment, sponsored by Sen. Bill Hagerty, removes explicit company names present in earlier drafts but keeps the core authority to limit government relationships with entities deemed national security risks. The Senate action revives a contentious debate around security, research collaboration, and the global biotech supply chain. Proponents argue the bill strengthens defenses against misuse of advanced biotechnologies; opponents, including many researchers, warn it risks disrupting scientific collaboration and supply chains without clear, evidence‑based criteria. The House passed a different defense bill without the Biosecure text, so reconciliation will determine final enactment. Companies and academic institutions flagged the measure as one to watch for contracting, international partnerships, and compliance planning this fall.